Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rapid test could free TB patients from isolation sooner

NCT ID NCT04968886

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study evaluates a rapid viability test for tuberculosis bacteria in sputum samples. The goal is to see if this test can accurately tell whether a patient is still contagious, compared to the standard culture method that takes weeks. If the test works, it could help doctors decide when it is safe to end isolation for hospitalized TB patients. The study includes 125 adults with smear-positive pulmonary TB who are already on treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
viability test on sputum
What this could lead to
If successful, this test could allow doctors to quickly determine if a TB patient is still contagious, reducing unnecessary isolation and improving patient care.
What could go wrong
This is a diagnostic study, not a treatment. The test may not be accurate enough to replace current methods, and results may vary across different settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

125 people

The number who actually took part.

Started

Oct 2022

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Smear-positive pulmonary tuberculosis patients.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 18 years old * Patient put on anti-tuberculosis treatment for pulmonary tuberculosis with at least one positive ME * Information given on the study and the right to oppose Exclusion Criteria: * Refusal of participation * People unable to understand the information, In accordance with article 11218 of the public health code, * people not affiliated with Health Insurance, * pregnant or breastfeeding women patients under legal protection can be included in a non-interventional study (type 3).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberculosis, pulmonary are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis, pulmonary

Contacts and locations

Locations

  • Benjamin WYPLOSZ

    Le Kremlin-Bicêtre, 94270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.